{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,30]],"date-time":"2026-06-30T21:06:16Z","timestamp":1782853576888,"version":"3.54.5"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2021,2,22]],"date-time":"2021-02-22T00:00:00Z","timestamp":1613952000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,2,22]],"date-time":"2021-02-22T00:00:00Z","timestamp":1613952000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/501100003769","name":"Eisai","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003769","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Breast Cancer"],"published-print":{"date-parts":[[2021,7]]},"DOI":"10.1007\/s12282-021-01224-1","type":"journal-article","created":{"date-parts":[[2021,2,22]],"date-time":"2021-02-22T10:02:57Z","timestamp":1613988177000},"page":"884-895","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["A transposon screen identifies enhancement of NF-\u03baB pathway as a mechanism of resistance to eribulin"],"prefix":"10.1007","volume":"28","author":[{"given":"Xiaozhong","family":"Teng","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1657-803X","authenticated-orcid":false,"given":"Tetsu","family":"Hayashida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takeshi","family":"Murata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aiko","family":"Nagayama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomoko","family":"Seki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maiko","family":"Takahashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuko","family":"Kitagawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,2,22]]},"reference":[{"key":"1224_CR1","doi-asserted-by":"publisher","first-page":"914","DOI":"10.1016\/S0140-6736(11)60070-6","volume":"377","author":"J Cortes","year":"2011","unstructured":"Cortes J, O\u2019Shaughnessy J, Loesch D, Blum JL, Vahdat LT, Petrakova K, et al. Eribulin monotherapy versus treatment of physician\u2019s choice in patients with metastatic breast cancer (EMBRACE): a phase 3 open-label randomised study. Lancet. 2011;377:914\u201323.","journal-title":"Lancet"},{"key":"1224_CR2","doi-asserted-by":"publisher","first-page":"594","DOI":"10.1200\/JCO.2013.52.4892","volume":"33","author":"PA Kaufman","year":"2015","unstructured":"Kaufman PA, Awada A, Twelves C, Yelle L, Perez EA, Velikova G, et al. Phase III open-label randomized study of eribulin mesylate versus capecitabine in patients with locally advanced or metastatic breast cancer previously treated with an anthracycline and a taxane. J Clin Oncol. 2015;33:594\u2013601.","journal-title":"J Clin Oncol"},{"key":"1224_CR3","doi-asserted-by":"publisher","first-page":"1525","DOI":"10.1093\/annonc\/mdw203","volume":"27","author":"X Pivot","year":"2016","unstructured":"Pivot X, Marme F, Koenigsberg R, Guo M, Berrak E, Wolfer A. Pooled analyses of eribulin in metastatic breast cancer patients with at least one prior chemotherapy. Ann Oncol. 2016;27:1525\u201331.","journal-title":"Ann Oncol"},{"key":"1224_CR4","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1038\/nrclinonc.2015.175","volume":"13","author":"MW Schmitt","year":"2016","unstructured":"Schmitt MW, Loeb LA, Salk JJ. The influence of subclonal resistance mutations on targeted cancer therapy. Nat Rev Clin Oncol. 2016;13:335\u201347.","journal-title":"Nat Rev Clin Oncol"},{"key":"1224_CR5","doi-asserted-by":"publisher","first-page":"4031","DOI":"10.21873\/anticanres.13559","volume":"39","author":"W Goto","year":"2019","unstructured":"Goto W, Kashiwagi S, Asano Y, Takada K, Takahashi K, Fujita H, et al. The effects of eribulin on breast cancer microenvironment identified using eribulin-resistant breast cancer cell lines. Anticancer Res. 2019;39:4031\u201341.","journal-title":"Anticancer Res"},{"key":"1224_CR6","doi-asserted-by":"publisher","first-page":"86594","DOI":"10.18632\/oncotarget.13358","volume":"7","author":"VB Sampson","year":"2016","unstructured":"Sampson VB, Vetter NS, Zhang W, Patil PU, Mason RW, George E, et al. Integrating mechanisms of response and resistance against the tubulin binding agent Eribulin in preclinical models of osteosarcoma. Oncotarget. 2016;7:86594\u2013607.","journal-title":"Oncotarget"},{"key":"1224_CR7","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1186\/1471-2407-13-93","volume":"13","author":"L Chen","year":"2013","unstructured":"Chen L, Stuart L, Ohsumi TK, Burgess S, Varshney GK, Dastur A, et al. Transposon activation mutagenesis as a screening tool for identifying resistance to cancer therapeutics. BMC Cancer. 2013;13:93.","journal-title":"BMC Cancer"},{"key":"1224_CR8","doi-asserted-by":"publisher","first-page":"867","DOI":"10.3892\/ijo.2015.3085","volume":"47","author":"M Tsutsui","year":"2015","unstructured":"Tsutsui M, Kawakubo H, Hayashida T, Fukuda K, Nakamura R, Takahashi T, et al. Comprehensive screening of genes resistant to an anticancer drug in esophageal squamous cell carcinoma. Int J Oncol. 2015;47:867\u201374.","journal-title":"Int J Oncol"},{"key":"1224_CR9","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1016\/j.molcel.2004.08.008","volume":"15","author":"A Kanayama","year":"2004","unstructured":"Kanayama A, Seth RB, Sun L, Ea CK, Hong M, Shaito A, et al. TAB2 and TAB3 activate the NF-kappaB pathway through binding to polyubiquitin chains. Mol Cell. 2004;15:535\u201348.","journal-title":"Mol Cell"},{"key":"1224_CR10","doi-asserted-by":"publisher","first-page":"366","DOI":"10.1002\/path.5144","volume":"246","author":"Y Li","year":"2018","unstructured":"Li Y, Deng L, Zhao X, Li B, Ren D, Yu L, et al. Tripartite motif-containing 37 (TRIM37) promotes the aggressiveness of non-small-cell lung cancer cells by activating the NF-kappaB pathway. J Pathol. 2018;246:366\u201378.","journal-title":"J Pathol"},{"key":"1224_CR11","doi-asserted-by":"publisher","first-page":"1042","DOI":"10.1158\/1541-7786.MCR-10-0196","volume":"9","author":"A Safina","year":"2011","unstructured":"Safina A, Sotomayor P, Limoge M, Morrison C, Bakin AV. TAK1-TAB2 signaling contributes to bone destruction by breast carcinoma cells. Mol Cancer Res. 2011;9:1042\u201353.","journal-title":"Mol Cancer Res"},{"key":"1224_CR12","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1016\/S0968-0896(02)00440-6","volume":"11","author":"M Tobe","year":"2003","unstructured":"Tobe M, Isobe Y, Tomizawa H, Nagasaki T, Takahashi H, Fukazawa T, et al. Discovery of quinazolines as a novel structural class of potent inhibitors of NF-kappa B activation. Bioorg Med Chem. 2003;11:383\u201391.","journal-title":"Bioorg Med Chem"},{"key":"1224_CR13","doi-asserted-by":"publisher","first-page":"21096","DOI":"10.1074\/jbc.272.34.21096","volume":"272","author":"JW Pierce","year":"1997","unstructured":"Pierce JW, Schoenleber R, Jesmok G, Best J, Moore SA, Collins T, et al. Novel inhibitors of cytokine-induced IkappaBalpha phosphorylation and endothelial cell adhesion molecule expression show anti-inflammatory effects in vivo. J Biol Chem. 1997;272:21096\u2013103.","journal-title":"J Biol Chem"},{"key":"1224_CR14","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1158\/2159-8290.CD-11-0073","volume":"1","author":"W Xue","year":"2011","unstructured":"Xue W, Meylan E, Oliver TG, Feldser DM, Winslow MM, Bronson R, et al. Response and resistance to NF-kappaB inhibitors in mouse models of lung adenocarcinoma. Cancer Discov. 2011;1:236\u201347.","journal-title":"Cancer Discov"},{"key":"1224_CR15","doi-asserted-by":"publisher","first-page":"1295","DOI":"10.1038\/s41467-019-09312-9","volume":"10","author":"EL Christie","year":"2019","unstructured":"Christie EL, Pattnaik S, Beach J, Copeland A, Rashoo N, Fereday S, et al. Multiple ABCB1 transcriptional fusions in drug resistant high-grade serous ovarian and breast cancer. Nat Commun. 2019;10:1295.","journal-title":"Nat Commun"},{"key":"1224_CR16","doi-asserted-by":"publisher","first-page":"1646","DOI":"10.1038\/nm.2580","volume":"17","author":"DR Robinson","year":"2011","unstructured":"Robinson DR, Kalyana-Sundaram S, Wu YM, Shankar S, Cao X, Ateeq B, et al. Functionally recurrent rearrangements of the MAST kinase and Notch gene families in breast cancer. Nat Med. 2011;17:1646\u201351.","journal-title":"Nat Med"},{"key":"1224_CR17","doi-asserted-by":"publisher","first-page":"2001","DOI":"10.1111\/jcmm.14102","volume":"23","author":"S Zhang","year":"2019","unstructured":"Zhang S, Zhang X, Sun Q, Zhuang C, Li G, Sun L, et al. LncRNA NR2F2-AS1 promotes tumourigenesis through modulating BMI1 expression by targeting miR-320b in non-small cell lung cancer. J Cell Mol Med. 2019;23:2001\u201311.","journal-title":"J Cell Mol Med"},{"key":"1224_CR18","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1038\/nature13955","volume":"516","author":"S Bhatnagar","year":"2014","unstructured":"Bhatnagar S, Gazin C, Chamberlain L, Ou J, Zhu X, Tushir JS, et al. TRIM37 is a new histone H2A ubiquitin ligase and breast cancer oncoprotein. Nature. 2014;516:116\u201320.","journal-title":"Nature"},{"key":"1224_CR19","doi-asserted-by":"publisher","first-page":"e1002532","DOI":"10.1371\/journal.pgen.1002532","volume":"8","author":"J Long","year":"2012","unstructured":"Long J, Cai Q, Sung H, Shi J, Zhang B, Choi JY, et al. Genome-wide association study in east Asians identifies novel susceptibility loci for breast cancer. PLoS Genet. 2012;8:e1002532.","journal-title":"PLoS Genet"},{"key":"1224_CR20","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1016\/j.molcel.2008.11.023","volume":"33","author":"S Li","year":"2009","unstructured":"Li S, Wang L, Dorf ME. PKC phosphorylation of TRAF2 mediates IKKalpha\/beta recruitment and K63-linked polyubiquitination. Mol Cell. 2009;33:30\u201342.","journal-title":"Mol Cell"},{"key":"1224_CR21","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1016\/j.ejphar.2003.09.034","volume":"481","author":"Y Hattori","year":"2003","unstructured":"Hattori Y, Hattori S, Kasai K. Lipopolysaccharide activates Akt in vascular smooth muscle cells resulting in induction of inducible nitric oxide synthase through nuclear factor-kappa B activation. Eur J Pharmacol. 2003;481:153\u20138.","journal-title":"Eur J Pharmacol"},{"key":"1224_CR22","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1038\/35085597","volume":"412","author":"C Wang","year":"2001","unstructured":"Wang C, Deng L, Hong M, Akkaraju GR, Inoue J, Chen ZJ. TAK1 is a ubiquitin-dependent kinase of MKK and IKK. Nature. 2001;412:346\u201351.","journal-title":"Nature"},{"key":"1224_CR23","doi-asserted-by":"publisher","first-page":"6910","DOI":"10.1038\/sj.onc.1203238","volume":"18","author":"M Barkett","year":"1999","unstructured":"Barkett M, Gilmore TD. Control of apoptosis by Rel\/NF-kappaB transcription factors. Oncogene. 1999;18:6910\u201324.","journal-title":"Oncogene"},{"key":"1224_CR24","doi-asserted-by":"publisher","first-page":"1680","DOI":"10.1126\/science.281.5383.1680","volume":"281","author":"CY Wang","year":"1998","unstructured":"Wang CY, Mayo MW, Korneluk RG, Goeddel DV, Baldwin AS Jr. NF-kappaB antiapoptosis: induction of TRAF1 and TRAF2 and c-IAP1 and c-IAP2 to suppress caspase-8 activation. Science. 1998;281:1680\u20133.","journal-title":"Science"},{"key":"1224_CR25","doi-asserted-by":"publisher","first-page":"998","DOI":"10.1126\/science.281.5379.998","volume":"281","author":"MX Wu","year":"1998","unstructured":"Wu MX, Ao Z, Prasad KV, Wu R, Schlossman SF. IEX-1L, an apoptosis inhibitor involved in NF-kappaB-mediated cell survival. Science. 1998;281:998\u20131001.","journal-title":"Science"},{"key":"1224_CR26","first-page":"107","volume":"63","author":"E Kikuchi","year":"2003","unstructured":"Kikuchi E, Horiguchi Y, Nakashima J, Kuroda K, Oya M, Ohigashi T, et al. Suppression of hormone-refractory prostate cancer by a novel nuclear factor kappaB inhibitor in nude mice. Cancer Res. 2003;63:107\u201310.","journal-title":"Cancer Res"},{"key":"1224_CR27","doi-asserted-by":"publisher","first-page":"3737","DOI":"10.1158\/0008-5472.CAN-12-3537","volume":"73","author":"KM Ahmed","year":"2013","unstructured":"Ahmed KM, Zhang H, Park CC. NF-kappaB regulates radioresistance mediated by beta1-integrin in three-dimensional culture of breast cancer cells. Cancer Res. 2013;73:3737\u201348.","journal-title":"Cancer Res"},{"key":"1224_CR28","doi-asserted-by":"publisher","first-page":"8167","DOI":"10.1158\/0008-5472.CAN-04-0970","volume":"64","author":"W Wang","year":"2004","unstructured":"Wang W, Cassidy J, O\u2019Brien V, Ryan KM, Collie-Duguid E. Mechanistic and predictive profiling of 5-Fluorouracil resistance in human cancer cells. Cancer Res. 2004;64:8167\u201376.","journal-title":"Cancer Res"},{"key":"1224_CR29","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1038\/nrd2781","volume":"8","author":"V Baud","year":"2009","unstructured":"Baud V, Karin M. Is NF-kappaB a good target for cancer therapy? Hopes and pitfalls. Nat Rev Drug Discov. 2009;8:33\u201340.","journal-title":"Nat Rev Drug Discov"},{"key":"1224_CR30","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1016\/j.ccell.2015.02.004","volume":"27","author":"B Liu","year":"2015","unstructured":"Liu B, Sun L, Liu Q, Gong C, Yao Y, Lv X, et al. A cytoplasmic NF-kappaB interacting long noncoding RNA blocks IkappaB phosphorylation and suppresses breast cancer metastasis. Cancer Cell. 2015;27:370\u201381.","journal-title":"Cancer Cell"},{"key":"1224_CR31","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1038\/nrd1279","volume":"3","author":"M Karin","year":"2004","unstructured":"Karin M, Yamamoto Y, Wang QM. The IKK NF-kappa B system: a treasure trove for drug development. Nat Rev Drug Discov. 2004;3:17\u201326.","journal-title":"Nat Rev Drug Discov"},{"key":"1224_CR32","doi-asserted-by":"publisher","first-page":"3177","DOI":"10.1182\/blood-2006-09-044974","volume":"109","author":"G Mulligan","year":"2007","unstructured":"Mulligan G, Mitsiades C, Bryant B, Zhan F, Chng WJ, Roels S, et al. Gene expression profiling and correlation with outcome in clinical trials of the proteasome inhibitor bortezomib. Blood. 2007;109:3177\u201388.","journal-title":"Blood"},{"key":"1224_CR33","doi-asserted-by":"publisher","first-page":"2177","DOI":"10.1182\/blood-2008-07-167767","volume":"112","author":"S Kumar","year":"2008","unstructured":"Kumar S, Rajkumar SV. Many facets of bortezomib resistance\/susceptibility. Blood. 2008;112:2177\u20138.","journal-title":"Blood"},{"key":"1224_CR34","doi-asserted-by":"crossref","unstructured":"Gao Y, Xiao X, Zhang C, Yu W, Guo W, Zhang Z, et al. Melatonin synergizes the chemotherapeutic effect of 5-fluorouracil in colon cancer by suppressing PI3K\/AKT and NF-kappaB\/iNOS signaling pathways. J Pineal Res. 2017;62","DOI":"10.1111\/jpi.12380"},{"key":"1224_CR35","first-page":"1876","volume":"5","author":"M Motwani","year":"1999","unstructured":"Motwani M, Delohery TM, Schwartz GK. Sequential dependent enhancement of caspase activation and apoptosis by flavopiridol on paclitaxel-treated human gastric and breast cancer cells. Clin Cancer Res. 1999;5:1876\u201383.","journal-title":"Clin Cancer Res"},{"key":"1224_CR36","doi-asserted-by":"publisher","first-page":"1171","DOI":"10.3892\/ijo.2014.2273","volume":"44","author":"H Hideshima","year":"2014","unstructured":"Hideshima H, Yoshida Y, Ikeda H, Hide M, Iwasaki A, Anderson KC, et al. IKKbeta inhibitor in combination with bortezomib induces cytotoxicity in breast cancer cells. Int J Oncol. 2014;44:1171\u20136.","journal-title":"Int J Oncol"},{"key":"1224_CR37","doi-asserted-by":"publisher","first-page":"6887","DOI":"10.1038\/sj.onc.1209982","volume":"25","author":"TD Gilmore","year":"2006","unstructured":"Gilmore TD, Herscovitch M. Inhibitors of NF-kappaB signaling: 785 and counting. Oncogene. 2006;25:6887\u201399.","journal-title":"Oncogene"},{"key":"1224_CR38","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1016\/j.it.2004.03.008","volume":"25","author":"G Bonizzi","year":"2004","unstructured":"Bonizzi G, Karin M. The two NF-kappaB activation pathways and their role in innate and adaptive immunity. Trends Immunol. 2004;25:280\u20138.","journal-title":"Trends Immunol"},{"key":"1224_CR39","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1038\/sj.bjc.6603906","volume":"97","author":"SJ Van Laere","year":"2007","unstructured":"Van Laere SJ, Van der Auwera I, Van den Eynden GG, van Dam P, Van Marck EA, Vermeulen PB, et al. NF-kappaB activation in inflammatory breast cancer is associated with oestrogen receptor downregulation, secondary to EGFR and\/or ErbB2 overexpression and MAPK hyperactivation. Br J Cancer. 2007;97:659\u201369.","journal-title":"Br J Cancer"},{"key":"1224_CR40","doi-asserted-by":"publisher","first-page":"1668","DOI":"10.1111\/j.1349-7006.2009.01228.x","volume":"100","author":"N Yamaguchi","year":"2009","unstructured":"Yamaguchi N, Ito T, Azuma S, Ito E, Honma R, Yanagisawa Y, et al. Constitutive activation of nuclear factor-kappaB is preferentially involved in the proliferation of basal-like subtype breast cancer cell lines. Cancer Sci. 2009;100:1668\u201374.","journal-title":"Cancer Sci"}],"container-title":["Breast Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12282-021-01224-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12282-021-01224-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12282-021-01224-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,6,18]],"date-time":"2021-06-18T15:25:43Z","timestamp":1624029943000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12282-021-01224-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,2,22]]},"references-count":40,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2021,7]]}},"alternative-id":["1224"],"URL":"https:\/\/doi.org\/10.1007\/s12282-021-01224-1","relation":{},"ISSN":["1340-6868","1880-4233"],"issn-type":[{"value":"1340-6868","type":"print"},{"value":"1880-4233","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,2,22]]},"assertion":[{"value":"30 July 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 February 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 February 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"T. Hayashida and Y. Kitagawa received research grants and lecture fees from Eisai Co., Ltd. A. Nagayama\u2019s immediate family member has a leadership position with Chugai Co., Ltd. and owns stock options of Chugai Co., Ltd. All remaining authors have no conflicts of interest to declare.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This article does not contain any studies with human participants performed by any of the authors. All applicable international, national, and\/or institutional guidelines for the care and use of animals were followed. All procedures performed in studies involving animals were in accordance with the ethical standards of Keio university.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Research involving human participants and\/or animals"}}]}}